01 1katwijk Chemie BV
01 1Lee Sung International Co., Ltd.
01 1Ethosuximide
01 1Netherlands
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2022-11-24
Registration Number : 20221124-211-J-1411
Manufacturer Name : katwijk Chemie BV
Manufacturer Address : Snijdersteaat 6, Katwijk Zh, 2222 BA, Netherlands
41
PharmaCompass offers a list of Ethosuximide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ethosuximide manufacturer or Ethosuximide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ethosuximide manufacturer or Ethosuximide supplier.
A CI 366 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CI 366, including repackagers and relabelers. The FDA regulates CI 366 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CI 366 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CI 366 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A CI 366 supplier is an individual or a company that provides CI 366 active pharmaceutical ingredient (API) or CI 366 finished formulations upon request. The CI 366 suppliers may include CI 366 API manufacturers, exporters, distributors and traders.
click here to find a list of CI 366 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a CI 366 Drug Master File in Korea (CI 366 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CI 366. The MFDS reviews the CI 366 KDMF as part of the drug registration process and uses the information provided in the CI 366 KDMF to evaluate the safety and efficacy of the drug.
After submitting a CI 366 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CI 366 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of CI 366 suppliers with KDMF on PharmaCompass.
